Najla El Jurdi
National Cancer Institute (NCI) · Masonic Cancer Center, University of Minnesota
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Najla El Jurdi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:04 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06303193 · Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI) · recruiting · Myelodysplastic Syndromes · principal investigator
- Ph1/Ph2NCT05918055 · Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesNational Cancer Institute (NCI) · terminated · Myelodysplastic Syndromes · principal investigator
- Ph1/Ph2NCT05531786 · Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)National Cancer Institute (NCI) · recruiting · Graft vs Host Disease · principal investigator
- Ph1/Ph2NCT05148234 · BMS-986253 in Myelodysplastic SyndromesNational Cancer Institute (NCI) · terminated · Myelodysplastic Syndromes · principal investigator
- N/ANCT03000244 · Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene TherapyNational Cancer Institute (NCI) · recruiting · Cellular Immunotherapy, Adoptive, Genetic Therapy, Tissue Donors · principal investigator
- Ph2NCT02988466 · Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCTMasonic Cancer Center, University of Minnesota · completed · Hematologic Malignancies · principal investigator
- Ph1/Ph2NCT02669251 · Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationNational Cancer Institute (NCI) · active not recruiting · Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome · principal investigator
- Ph2NCT01688466 · Pomalidomide for Chronic Graft-versus-Host DiseaseNational Cancer Institute (NCI) · completed · Graft vs Host Disease, Graft-Versus-Host Disease · principal investigator
- Ph2NCT01557517 · Clobetasol for Oral Graft-Versus-Host DiseaseNational Cancer Institute (NCI) · completed · Oral Chronic Graft vs Host Disease · principal investigator
- Ph2NCT00432094 · Autologous Peripheral Blood Stem Cell Transplant for Germ Cell TumorsMasonic Cancer Center, University of Minnesota · completed · Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma · principal investigator
- N/ANCT00092235 · Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host DiseaseNational Cancer Institute (NCI) · recruiting · Chronic Graft vs. Host Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:04 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.Transplant Cell Ther · 202330 citationsRCR 3.3
- Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.Transplant Cell Ther · 202313 citationsRCR 1.1